ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
澳股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
新冠治疗股
916.310
-4.868
-0.53%
涨家数:
9
跌家数:
10
平家数:
13
市盈率:
- -
高:
920.146
开:
917.739
低:
913.980
收:
921.178
成交量:
1,964.92万
成交额:
1.77亿
市值:
2,360.43亿
流通市值:
1,841.69亿
数据加载中...
总览
新闻资讯
Mesoblast宣布James M. O’Brien被任命为首席财务官
投资观察
·
1小时前
新闻稿:詹姆斯·M·奥布莱恩被任命为美莎比信托首席财务官
投资观察
·
2小时前
ADVANCE ZINCTEK LTD - FDA确认其2024年4月信中提到的问题已 satisfactorily 解决
美股速递
·
5小时前
BUZZ-奥布莱恩出任美国分部财务总监,Mesoblast 的澳大利亚股票攀升
路透中文
·
8小时前
Mesoblast将于下月与FDA会谈讨论Rexlemestrocel-L和阿片类药物戒断
投资观察
·
11/05
Mesoblast将于下月与FDA会面讨论Rexlemestrocel-L和药物戒断
美股速递
·
11/05
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK7501/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"新冠治疗股","latestPrice":916.30975,"timestamp":1763355599949,"preClose":921.1781,"halted":0,"volume":19649157,"delay":0,"changeRate":-0.005285,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-4.868347,"latestTime":"11-17 16:00:00 AEDT","open":917.7388,"high":920.14594,"low":913.9801,"amount":177174034,"amplitude":0.006693,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1763420400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1763334000000,1763355600000]],"turnoverRate":0.001371,"increases":8,"decrements":11,"flats":13,"marketCap":236042640020.25,"floatMarketCap":184168708055.83594},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":920.14594,"amplitude":0.006693,"preClose":921.1781,"low":913.9801,"latestPrice":916.30975,"volume":19649157,"delay":0,"open":917.7388,"prevYearClose":1117.913,"prevWeekClose":921.178,"prevMonthClose":914.468,"prevQuarterClose":950.171,"fiveDayClose":910.822,"twentyDayClose":999.431,"sixtyDayClose":1016.53,"secType":"PLATE","market":"AU","turnoverRate":0.001371,"marketCap":236042640020.25,"floatMarketCap":184168708055.83594,"timestamp":1763355599949,"nameCN":"新冠治疗股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":9,"down":10,"flat":13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1182398223","title":"Mesoblast宣布James M. O’Brien被任命为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1182398223","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182398223?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:14","pubTimestamp":1763367269,"startTime":"0","endTime":"0","summary":"11月17日 - Mesoblast Ltd:James M. O’Brien被任命为Mesoblast的首席财务官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"1195991725","title":"新闻稿:詹姆斯·M·奥布莱恩被任命为美莎比信托首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1195991725","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195991725?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 14:56","pubTimestamp":1763362561,"startTime":"0","endTime":"0","summary":"纽约,2025年11月17日-- 美莎比信托,全球领先的用于治疗炎症性疾病的同种异体细胞药物公司,今天宣布,在公司向一个完全整合的商业组织转型之际,任命詹姆斯·M·奥布莱恩为其美国首席财务官。詹姆斯在财务管理和规划的各个方面拥有丰富经验,职业生涯的大部分时间都在生命科学、生物技术和制药行业的跨国公私公司中度过。本发布已获首席执行官授权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFO","BK4139","BK4150","BK4022","MSB.AU","BK4575","BK4006","MSB","BMS","BK7067","BK7501","BK7508","MESO","R","MSC","BK4232"],"gpt_icon":0},{"id":"1180454626","title":"ADVANCE ZINCTEK LTD - FDA确认其2024年4月信中提到的问题已 satisfactorily 解决","url":"https://stock-news.laohu8.com/highlight/detail?id=1180454626","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180454626?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 12:06","pubTimestamp":1763352376,"startTime":"0","endTime":"0","summary":"ADVANCE ZINCTEK LTD - FDA确认其2024年4月信中提到的问题已 satisfactorily 解决","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7036","BK7501","ANO.AU"],"gpt_icon":0},{"id":"2584924916","title":"BUZZ-奥布莱恩出任美国分部财务总监,Mesoblast 的澳大利亚股票攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924916","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924916?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 09:11","pubTimestamp":1763341883,"startTime":"0","endTime":"0","summary":"11月17日 - ** 在澳大利亚证券交易所上市的炎症性疾病药物生产商Mesoblast MSB.AX的股价上涨3.6%,达到2.3澳元,结束了连续两个交易日的下跌。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nL4T3WT01H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CGTX","BK7501","MSB.AU","BK7067","BK4007"],"gpt_icon":0},{"id":"1116191251","title":"Mesoblast将于下月与FDA会谈讨论Rexlemestrocel-L和阿片类药物戒断","url":"https://stock-news.laohu8.com/highlight/detail?id=1116191251","media":"投资观察","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116191251?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 09:45","pubTimestamp":1762307124,"startTime":"0","endTime":"0","summary":"11月5日(路透社) - Mesoblast Ltd:*MESOBLAST将于下月与FDA会面,讨论Rexlemestrocel-L和阿片类药物戒断* 进一步公司报道:MSB.AX","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","MSB.AU"],"gpt_icon":0},{"id":"1199521939","title":"Mesoblast将于下月与FDA会面讨论Rexlemestrocel-L和药物戒断","url":"https://stock-news.laohu8.com/highlight/detail?id=1199521939","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199521939?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 06:59","pubTimestamp":1762297168,"startTime":"0","endTime":"0","summary":"Mesoblast将于下月与FDA会面,讨论Rexlemestrocel-L和药物戒断的相关事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MESO","MSB.AU","BK4139","BK7508","BK7501"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}